Quality Risk-Management Principles and PQRI Case Studies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality Risk-Management Principles and PQRI Case Studies
A PQRI expert working group provides case study examples of risk-management applications.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 72-76

Conclusion

The PQRI–MTC Risk Management Working Group solicited and formatted a series of best-practice case studies aligned with ICH Q9 principles. The collected case studies demonstrate that there is a wide range of applications for the use of structured risk-management analysis to facilitate effective quality-decision activities. The studies demonstrate the baseline needed to choose the appropriate risk methodology for the targeted need, taking into account the degree of complexity and risk involved for the specific subject of concern. It is equally important to predefine the potential resulting risk categorizations so as to not be influenced by the assessment results in defining appropriate response actions. Finally, once risks have been appropriately assessed and prioritized, clear risk-mitigating actions must be defined, communicated, implemented and monitored for effectiveness.

Ted Frank is with Merck & Co; Stephen Brooks, Kristin Murray* and Steve Reich are with Pfizer; Ed Sanchez is with Johnson & Johnson; Brian Hasselbalch is with the FDA Center for Drug Evaluation and Research; Kwame Obeng is with Bristol Myers Squibb; and Richard Creekmore is with AstraZeneca.

*To whom all correspondence should be addressed,
.

References

1. FDA Global Harmonization Task Force, "Implementation of Risk Management Principles andActivities within a Quality Management System" (Rockville, MD, 2000).

2. ICH, Q9 Quality Risk Management, 2005.

3. FDA, Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations (Rockville, MD, 2006).

4. FDA, "Risk-Based Method for Prioritizing CGMP Inspections of Pharmaceutical Manufacturing Sites–A Pilot Risk Ranking Model," (Rockville, MD, 2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here